Volume 13, Number 8—August 2007
Letter
Threat to Cefixime Treatment for Gonorrhea
Shigeaki Yokoi*, Takashi Deguchi*
, Tomomi Ozawa*, Mitsuru Yasuda*, Shin-ichi Ito*, Yasuaki Kubota†, Masayoshi Tamaki†, and Shin-ichi Maeda†
, Tomomi Ozawa*, Mitsuru Yasuda*, Shin-ichi Ito*, Yasuaki Kubota†, Masayoshi Tamaki†, and Shin-ichi Maeda†
Table
Antimicrobial drug susceptibilities of clinical isolates of Neisseria gonorrhoeae from patients with gonococcal urethritis treated unsuccessfully with a 3-day cefixime regimen*
| Patient | MIC (μg/mL) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Isolate | PCG | TET | CFX | CFD | CDZ | CTX | LVF | AZM | SPC | |
| 1 | Pre-Tx | 4 | 2 | 0.5 | 1 | 0.125 | 0.125 | 16 | 0.25 | 16 |
| Post-Tx | 4 | 2 | 0.5 | 1 | 0.125 | 0.125 | 16 | 0.125 | 32 | |
| 2 | Pre-Tx | 8 | 4 | 0.5 | 1 | 0.25 | 0.5 | 8 | 0.5 | 32 |
| Post-Tx | 8 | 2 | 0.5 | 1 | 0.125 | 0.25 | 8 | 0.5 | 16 | |
| 3 | Pre-Tx | 4 | 2 | 1 | 2 | 0.25 | 0.125 | 16 | 0.25 | 16 |
| Post-Tx | 4 | 2 | 1 | 2 | 0.25 | 0.125 | 16 | 0.25 | 16 | |
| 4 | Pre-Tx | 4 | 1 | 1 | 2 | 0.25 | 0.25 | 16 | 0.125 | 16 |
| Post-Tx | 4 | 2 | 1 | 2 | 0.25 | 0.25 | 16 | 0.25 | 32 | |
*PCG, penicillin G; TET, tetracycline; CFX, cefixime; CFD, cefdinir; CDZ, cefodizime; CTX, ceftriaxone; LVF, levofloxacin; AZM, azithromycin; SPC, spectinomycin; Pre-Tx, isolate recovered before cefixime treatment; Post-Tx, isolate recovered after cefixime treatment, i.e., before ceftriaxone treatment.
Page created: June 30, 2010
Page updated: June 30, 2010
Page reviewed: June 30, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.